Skip to main content
Premium Trial:

Request an Annual Quote

CML HealthCare Licenses Rights to XDx's AlloMap

NEW YORK (GenomeWeb News) – CML HealthCare and XDx jointly announced today that CML has licensed exclusive rights to market XDx's AlloMap test initially in Ontario, Canada but with an option to extend the rights across the country.

Mississauga, Ontario-based CML, a publicly held diagnostic services provider, expects to begin offering the test later this summer. Financial and other terms of the alliance were not disclosed.

XDx's AlloMap measures the expression levels of a set of genes from a blood sample, providing clinicians a tool for evaluating a patient's risk for a heart transplant rejection. The company launched the test in 2005, and three years later the US Food and Drug Administration approved AlloMap.

The Brisbane, Calif.-based firm recently signed a memorandum of understanding that would provide an exclusive license to Diaxonhit for the AlloMap test in Europe. That deal would make Diaxonhit XDx's exclusive partner on the continent.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.